Abstract: An adaptive adjustment system and method for the brightness of a holographic waveguide display device is provided. The adaptive adjustment system includes five functional modules: a computer control module, a driving and adjustment module, a micro image source display module, an optical waveguide transmission module and an ambient light acquisition module. A video signal is provided by the computer control module and is then transmitted under the control of the driving and adjustment module to illuminate the micro image source display module, and light information of the micro image source display module is finally transmitted to human eyes by means of the optical waveguide transmission module to realize display. The ambient light acquisition module is used for acquiring environmental illuminance information and transmitting the environmental illuminance information to the driving and adjustment module to change the brightness of the micro image source display module.

Abstract: An adaptive adjustment system and method for the brightness of a holographic waveguide display device is provided. The adaptive adjustment system includes five functional modules: a computer control module, a driving and adjustment module, a micro image source display module, an optical waveguide transmission module and an ambient light acquisition module. A video signal is provided by the computer control module and is then transmitted under the control of the driving and adjustment module to illuminate the micro image source display module, and light information of the micro image source display module is finally transmitted to human eyes by means of the optical waveguide transmission module to realize display. The ambient light acquisition module is used for acquiring environmental illuminance information and transmitting the environmental illuminance information to the driving and adjustment module to change the brightness of the micro image source display module.

Abstract: The present disclosure provides herein conjugates of anti-CLDN18.2 antibodies or antigen-binding fragments thereof with radionuclides, the pharmaceutical composition containing the same and the uses thereof in imaging, patient screening, treatment process monitoring and efficacy evaluation.

Abstract: A stabilized aPGF composition or a method for stabilization of the pharmaceutical composition comprising aFGF are provided. The composition comprises aPGF, a citric acid compound and other excipients. The method for improving stability of aPGF in the form of a liquid formulation or a lyophilized formulation so as to increase storage stability is also provided.

Abstract: A high-adsorption-performance nanofiber filter medium includes a support material and a composite nanofiber filtration layer that includes multiple nanometer composite nanofiber layers deposited and stacked on the support material. The nanometer composite nanofiber layer includes first, second, and third nano-powder composite nanofibers, which are uniformly mixed by means of an airflow or are sequentially laminated to form the nanometer composite nanofiber layer. The nanometer composite nanofiber layer formed through sequential lamination includes first, second, and third nanofiber layers. The first nanofiber layer includes multiple first nano-powder composite nanofibers. The second nanofiber layer is stacked on the first nanofiber layer and includes multiple second nano-powder composite nanofibers. The third nanofiber layer is stacked on the second nanofiber layer and includes multiple third nano-powder composite nanofibers.

Abstract: A stabilized aFGF composition or a method for stabilization of the pharmaceutical composition comprising aFGF are provided. The composition comprises aFGF, a citric acid compound and other excipients. The method for improving stability of aFGF in the form of a liquid formulation or a lyophilized formulation so as to increase storage stability is also provided.

Abstract: The present invention relates to injectable, extended-release, pharmaceutical formulations comprising a nalbuphine ester prodrug homogenously dissolved in a solution comprising a pharmaceutically acceptable oil and an oil-miscible retaining solvent, as well as manufacturing processes and medical uses of the formulations. The invention further provides methods for adjusting the duration of action of the formulations by varying the ratio of the pharmaceutically acceptable oil and the oil-miscible retaining solvent.

Abstract: The present invention relates to injectable, extended-release, pharmaceutical formulations comprising a nalbuphine ester prodrug homogenously dissolved in a solution comprising a pharmaceutically acceptable oil and an oil-miscible retaining solvent, as well as manufacturing processes and medical uses of the formulations. The invention further provides methods for adjusting the duration of action of the formulations by varying the ratio of the pharmaceutically acceptable oil and the oil-miscible retaining solvent.

Abstract: The present invention relates to injectable, extended-release, pharmaceutical formulations comprising a nalbuphine ester prodrug homogenously dissolved in a solution comprising a pharmaceutically acceptable oil and an oil-miscible retaining solvent, as well as manufacturing processes and medical uses of the formulations. The invention further provides methods for adjusting the duration of action of the formulations by varying the ratio of the pharmaceutically acceptable oil and the oil-miscible retaining solvent.

Abstract: A high-adsorption-performance nanofiber filter medium includes a support material and a composite nanofiber filtration layer that includes multiple nanometer composite nanofiber layers deposited and stacked on the support material. The nanometer composite nanofiber layer includes first, second, and third nano-powder composite nanofibers, which are uniformly mixed by means of an airflow or are sequentially laminated to form the nanometer composite nanofiber layer. The nanometer composite nanofiber layer formed through sequential lamination includes first, second, and third nanofiber layers. The first nanofiber layer includes multiple first nano-powder composite nanofibers. The second nanofiber layer is stacked on the first nanofiber layer and includes multiple second nano-powder composite nanofibers. The third nanofiber layer is stacked on the second nanofiber layer and includes multiple third nano-powder composite nanofibers.

Abstract: Disclosed are methods and compositions useful in preventing or treating a metabolic disorder by using a protein having an amino acid sequence as set forth in SEQ ID NO: 1.

Abstract: A portable breathing machine includes a body case (100), wherein: a fan box (101), a cut-off device (108) and a control device (113) are arranged in the body case (100); a fan (8) is arranged in the fan box (101) through a fan noise reduction device (102); an air outlet of the fan box (101) is connected with an internal breathing tube (107); the cut-off device (108) is arranged on the internal breathing tube (107); an air outlet of the cut-off device (108) is connected with an external breathing tube (104) and a mask (105); the fan noise reduction device (102) includes a lower flexible cover (3) and an upper flexible cover (5); the lower and upper flexible covers cooperate to form an enclosed cavity for containing the fan (8). A working noise of the breathing machine is decreased to below 15 decibel.

Abstract: Disclosed are methods and compositions useful in preventing or treating a metabolic disorder by using a protein having an amino acid sequence as set forth in SEQ ID NO: 1.

Abstract: The present invention relates to injectable, extended-release, pharmaceutical formulations comprising a nalbuphine ester prodrug homogenously dissolved in a solution comprising a pharmaceutically acceptable oil and an oil-miscible retaining solvent, as well as manufacturing processes and medical uses of the formulations. The invention further provides methods for adjusting the duration of action of the formulations by varying the ratio of the pharmaceutically acceptable oil and the oil-miscible retaining solvent.

Abstract: The present invention relates to injectable, extended-release, pharmaceutical formulations comprising a nalbuphine ester prodrug homogenously dissolved in a solution comprising a pharmaceutically acceptable oil and an oil-miscible retaining solvent, as well as manufacturing processes and medical uses of the formulations. The invention further provides methods for adjusting the duration of action of the formulations by varying the ratio of the pharmaceutically acceptable oil and the oil-miscible retaining solvent.

Abstract: The present invention relates to kits and prefilled syringes comprising pharmaceutical formulations comprising a nalbuphine ester prodrug homogenously dissolved in a solution comprising a pharmaceutically acceptable oil and an oil-miscible retaining solvent, as well as methods of treating pain using such formulations.

Abstract: The present invention includes a toilet pool, wherein the toilet pool has a pool tapered from top to bottom, the bottom of the pool is a discharge outlet, the top of the pool is a tapered annular platform, the tapered annular platform consists of a wide part and a narrow part, above the tapered annular platform is a slot flush nozzle, shunts implemented by the slot flush nozzle are evenly distributed on a surface of the pool under the guide of the tapered annular platform, and the toilet pool is provided with a clean water supply. It achieves a configuration that two flushing systems coexist on a toilet pool, achieves secondary homogenization of water currents, achieves water-saving and efficient flushing, achieves maximization of water capacity in the same space, and achieves a simple, reliable fixedly-installed toilet.

Abstract: A lighting device is disclosed. The lighting device comprises: a solid-state lighting element; a radio frequency communication unit for wireless communication between the lighting device and an external device; a light guide having a circumferential edge, wherein the light guide is adapted to couple in light emitted by the solid-state lighting element and to provide illumination to the surroundings of the lighting device; and a metal strip extending along at least a portion of the circumferential edge of the light guide, wherein the metal strip is in thermal contact with the solid-state lighting element and the light guide, and wherein the metal strip is coupled to the radio frequency communication unit so as to operate as an antenna for the radio frequency communication unit.

Abstract: The present invention relates to injectable, extended-release, pharmaceutical formulations comprising a nalbuphine ester prodrug homogenously dissolved in a solution comprising a pharmaceutically acceptable oil and an oil-miscible retaining solvent, as well as manufacturing processes and medical uses of the formulations. The invention further provides methods for adjusting the duration of action of the formulations by varying the ratio of the pharmaceutically acceptable oil and the oil-miscible retaining solvent.

Abstract: The present invention relates to injectable, extended-release, pharmaceutical formulations comprising a nalbuphine ester prodrug homogenously dissolved in a solution comprising a pharmaceutically acceptable oil and an oil-miscible retaining solvent, as well as manufacturing processes and medical uses of the formulations. The invention further provides methods for adjusting the duration of action of the formulations by varying the ratio of the pharmaceutically acceptable oil and the oil-miscible retaining solvent.